The treatment landscape for patients with HER2-postive breast cancer is still evolving, with current options now including HER2-targeted mAbs, antibody–drug conjugates (ADC), and small-molecule tyrosine kinase inhibitors (TKI); however, patients’ disease often develops resistance and progresses on therapy. This evidence concerns the gene ERBB2 and breast carcinoma.